21st.BIO earns GRAS status for animal-free beta-lactoglobulin ingredient

Precision fermentation platform provider 21st.BIO has earned a self-affirmed GRAS status for its animal-free beta-lactoglobulin ingredient, BLG Essential+, which means customers can now launch in the US market

This breakthrough comes less than two years after 21st.BIO initiated its development of a strain and production process for its beta-lactoglobulin protein, BLG Essential+, demonstrating the power of the Company's approach, unique expertise and differentiated precision fermentation platform.

Through 21st.BIO's BLG programme, customers gain access to the world's most advanced production strains and precision fermentation processes - and optimisations over time. Furthermore, 21st.BIO is supporting customers in upscaling their production all the way to full-scale ingredient production. The Company's diverse global customer base spans food-tech start-ups to large food ingredients manufacturers. BLG Essential+ is the first food protein out of a portfolio of protein ingredients that 21st.BIO will take to the market via this model. 

With a strong track record and productive microorganisms licensed from Novonesis (formerly Novozymes), 21st.BIO is bringing solutions to market at an unprecedented pace, enabling customers to bypass years of development and market approval for direct entry into the US market and empowering customers to produce any food, materials, agriculture, or biopharma-related protein or peptide of interest, and scale production to industrial levels to ensure large-scale availability and cost-effectiveness.  

"We're not just a technology provider - we're a partner to our customers' on their product journey, ensuring their success from development to full-scale manufacturing. We make products, not projects," said 21st.BIO co-founder and CEO Thomas G. Schmidt. "Our ambition is to empower our customers to focus more on application, business development, low-cost production and innovation. And this shows all the way through our business model, which is designed such that our success at 21st.BIO depends on our customers' success in the market with a product; not just on project completion."